Companies › SANGMYUNG innovation
2 active drug programs in 2 registered trials: 2 Phase 3; Ophthalmology; next expected readout Jul 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SMO1 Dexamethasone 700μg intravitreal implant | – | Phase 3 | Retinal Vein Occlusion With Macular Edema | Jul 2027 |
| SMZ1 | – | Phase 3 | Neovascular (Wet) Age-related Macular Degeneration Without Polypoidal Choroidal Vasculopathy | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07708142 | SMO1 | Phase 3 | Retinal Vein Occlusion With Macular Edema | Ophthalmology | Jul 2027 |
| NCT07695207 | SMZ1 | Phase 3 | Neovascular (Wet) Age-related Macular Degeneration Without Polypoidal Choroidal Vasculopathy | Ophthalmology | Dec 2027 |
No annotated target.
–
Cloudbreak Therapeutics Omikron Italia S.r.l. Viridian Therapeutics Aurion Biotech Smilebiotek Zhuhai
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.